Adverse Reactions to Anthrax Immunisation in a Military Field Hospital
S C Hayes, M J World

Objective
To determine the outcome of anthrax immunisation.

Methods
Adverse reactions (occurrence, nature, severity and incapacity) and immune responses to a voluntary programme of anthrax immunisation at 0, 3, 6, and 24 weeks were monitored by questionnaire and voluntary blood sampling in 129 members, including 24 immunised 7 years previously (immunes), of a military field hospital alerted for possible deployment.

Results
Follow-up was complete in 85%. Ninety-eight (76%) received the first anthrax immunisation. Uptake was greater (p=0.015) in immunes. Initial prevalence of adverse reaction was 63%. Subsequent uptake and adverse reaction dwindled significantly (p<0.001). Only 28 (22%) were immunised at 24 weeks. Proportions reporting adverse reactions following the initial immunisation were greater in immunes (p=0.046) and officers (p=0.02). There was no significant (p=0.36) correlation between uptake of immunisation and prevalence of adverse reaction. Antecedent adverse reaction did not reduce the proportion of participants accepting immunisation subsequently. The nature of adverse reactions (47% local, 24% systemic and 27% both) and severity were the same throughout. Forty-five percent of adverse reactions caused incapacity. Seventy-four percent of these had pain in the injected arm (+ systemic symptoms) which prevented lifting or driving for 48 hours in 63%. Immune responses were greater in immunes.

Conclusions
It was concluded that anthrax immunisation results in a higher than expected prevalence of adverse reaction with initial incapacity of military significance affecting 18%. Greater immune responses may increase adverse reaction but this does not affect acceptance of anthrax immunisation.

Introduction
Voluntary Immunisation
In March 1998, a military field hospital was alerted for possible deployment and 129 members were listed to receive intramuscular immunisations with anthrax vaccine at 0, 3, 6 and 24 weeks. This was voluntary in response to concerns of Gulf War 1990/1991 veterans that, amongst others, anthrax immunisation could cause "Gulf War Syndrome".

Anticipated prevalence of side effects
Between 1976 and 1998, the Committee on the Safety of Medicines (CSM) received 19 reports of adverse reactions at a time when about 2200 doses of anthrax vaccine were issued annually. Only 10-15% of serious reactions may be reported to the CSM. Hence, with a possible total of 516 doses being administered, only one or two adverse reactions were expected and sick parade was considered satisfactory surveillance. However, when several personnel who had not attended sick parade mentioned having had significant adverse reactions following the first immunisation, a study was rapidly devised to elicit reports and to assess the relation to the immune response following each immunisation.

Methods
Data acquisition
Personal information and any previous immunisation were recorded. After each immunisation, a questionnaire (copies available from MJW) about any adverse reaction (nature, severity and associated incapacity) was provided. A copy was sent to absentees. Subject to written informed consent, a 5ml blood sample was taken and serum was stored at -80°C Celsius for enzyme-linked immunosorbent assay (ELISA) for IgG to recombinant protective antigen.

Statistical Analysis
When sample variances were homoscedastic by F-test, the significance of differences between two mean values was assessed using Student’s t-test and otherwise of medians by Mann-Whitney U-test.
Differences between three or more mean values were assessed by one-way ANOVA. The significance of differences in proportions in contingency tables was assessed by χ²-test or Fisher's exact test as appropriate. Where trends were suspected in contingency tables, χ²-test for trend was applied. Linear correlation between continuous variables was assessed by the method of least squares and the significance of the correlation coefficient assessed by Student's t-test. Statistical significance was considered to exist in all circumstances when p<0.05.

Results

Completeness of response
Follow-up was complete in 110 (85%). Of the remaining 19 not contacted, only 4 received the first anthrax immunisation and personal details of 4 were available from staff records.

Personnel
Fifty-eight (45%) were permanent staff reinforced by 56 (43%) from a military hospital and 15 (12%) from other units. Demography is shown in Table 1. All but 5 (4%) of 114 were Caucasian. Twenty-four (19%) had anthrax immunisation 7 years previously (immunes) during the Gulf War (1990/91). Anthrax immunisation status of 25 (19%) was undetermined.

<table>
<thead>
<tr>
<th>Total</th>
<th>Males</th>
<th>Females</th>
<th>Gender</th>
<th>Unrecorded</th>
</tr>
</thead>
<tbody>
<tr>
<td>Officers</td>
<td>97 (36%)</td>
<td>28 (59%)</td>
<td>17 (36%)</td>
<td>2 (4%)</td>
</tr>
<tr>
<td>Mean Age (yr)</td>
<td>35.61</td>
<td>38.07</td>
<td>31.19</td>
<td></td>
</tr>
<tr>
<td>(±SD; n)</td>
<td>(+±6.67;42)</td>
<td>(+±3.27;27)</td>
<td>(+±3.82;15)</td>
<td></td>
</tr>
<tr>
<td>Other Ranks</td>
<td>240 (64%)</td>
<td>53 (57%)</td>
<td>21 (26%)</td>
<td>8 (10%)</td>
</tr>
<tr>
<td>Mean Age (yr)</td>
<td>29.19</td>
<td>29.21</td>
<td>29.13</td>
<td></td>
</tr>
<tr>
<td>(±SD; n)</td>
<td>(+±4.66;73)</td>
<td>(+±4.95;52)</td>
<td>(+±3.81;21)</td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>129 (100%)</td>
<td>83 (63%)</td>
<td>38 (29%)</td>
<td>10 (8%)</td>
</tr>
</tbody>
</table>

Table 1. Demography of the military field hospital.

The proportions of males and females were not statistically significantly different between the Officers and Other Ranks (χ²[Yates' continuity corrected] = 0.7461, df = 1; p = 0.39). The mean age of Officers was higher than that of Other Ranks and this difference was statistically significant (variances were heterogeneous F=2.045, DFn=41, Dfd=51, p=0.0039; Mann-Whitney U=660.5, p<0.0001). This difference in age was due to the higher mean age of Male Officers when compared with that of Male Other Ranks. This difference was statistically significant (variances were heterogeneous F=1.788, DFn=26, Ddf=51, p=0.038; Mann-Whitney U=190, p<0.0001) Mean ages of Female Officers and Female Other ranks were not statistically significantly different (ż=1.10 - 11.42). Gender had no effect (p=0.66. Data not shown) Officers had increased risk (p<0.02. Data not shown) but were older. However, when all subjects were stratified by quartiles according to age, there was no significant trend for the prevalence of adverse reaction to increase with age (p=0.44. Data not shown).

Factors affecting acceptance of the first anthrax immunisation

Prevalence of adverse reaction

Table 2. The proportions of subjects who did and did not report an adverse reaction to anthrax immunisation at each stage of the schedule were statistically significantly different with a highly statistically significant trend towards reduced prevalence of adverse reaction as time passed (χ²=38.35, df=3; p<0.0001; χ² for trend=18.67, df=1; p<0.0001)

Factors affecting report of an adverse reaction to anthrax immunisation

Effect of an adverse reaction to antecedent anthrax immunisation on the prevalence of adverse reaction to a subsequent immunisation

Antecedent adverse reactions were found to affect the prevalence of adverse reaction to subsequent anthrax immunisation only at 6 weeks when the proportion of those reporting adverse reactions at 0 and 3 weeks who also had an adverse reaction at 6 weeks (7/12) was greater than that (0/7) who did not report adverse reactions at 0 and 3 weeks (p=0.02. Difference in proportions = 0.58 [95% CI 0.30 - 0.86]; odds ratio = ∞).
Lack of correlation between acceptance of anthrax immunisation and prevalence of adverse reaction

No correlation between acceptance of anthrax immunisation and prevalence of adverse reaction was found ($r=0.64$; $p=0.36$).

Effect of a preceding adverse reaction on the acceptance of a subsequent immunisation

Antecedent adverse reaction was found to affect subsequent immunisation only once and then favourably. The proportion of those reporting adverse reactions at 0 weeks and 3 weeks who received immunisation at 6 weeks (12/13) was greater than that (7/22) of those who did not report adverse reactions at 0 and 3 weeks and had immunisation at 6 weeks ($p=0.001$. Difference in proportions $= 0.453$ [95% CI 0.36 - 0.84]; odds ratio $= 25.71$ [95% CI 2.74 - 239.51]).

Classification of diverse reactions and prevalence following each immunisation

The distribution between three mutually exclusive categories of adverse reaction did not change at any stage ($p=0.55$). Overall, 47% experienced local (pain at the injection site) reactions, 24% systemic (mainly influenza-like) reactions and 27% both (data not shown).

Severity of adverse reactions

This did not change during the immunisation schedule ($p=0.75$. Data not shown). Overall, 29% of reactions were classified as mild, 49% moderate and 21% severe.

Incapacity

The proportion of personnel reporting incapacity as a result of adverse reactions did not differ at any stage ($p=0.75$. Data not shown). Whatever the adverse reaction, 49% were incapacitated ($p=0.09$. Data not shown). The distribution of incapacitated personnel between the three categories of adverse reaction did not change during the immunisation schedule ($p=0.76$. Data not shown). Twenty-seven (63%) of the 43 reports of incapacity mentioned the duration, the distribution of which was the same throughout the schedule ($p=0.1$, Data not shown). Overall, the duration of the majority (63%) of incapacitating adverse reactions (mainly pain at the site of injection preventing lifting or driving) did not exceed 48 hours. The maximum duration of incapacity was 120 hours.

Immune responses

Concentrations of IgG to recombinant protective antigen at different times are shown in the figure. Wide variation is apparent. Mean antibody levels were generally higher in immunes being statistically significant at 3 weeks ($p=0.006$) and 24 weeks ($p=0.006$). A trend towards a rise in concentration was seen in the naive but mean values were not statistically significant different ($p=0.59$).

Discussion

Protection against anthrax

Anthrax spores are a potent biological weapon (1). Fatal pulmonary anthrax results when sufficient spores are inhaled unless some effective preventive measure is taken (2). Immunisation is one method (3). Pure recombinant protective antigen administered with Ribi adjuvant to experimental animals is encouraging (4) but has yet to be assessed in man. Although the old vaccine is considered safe, the number of adverse reactions and incapacity reported by a military medical unit was unexpected.

Completion of immunisation schedule

Initial acceptance of immunisation (76%) was comparable to that (78%) reported in American mill workers not withdrawn from a clinical trial (5). In the present study, only 27 (21% of those initially listed) completed the immunisation schedule. A lower fall in uptake was found when civilian volunteers were immunised (6). Continuing exposure to anthrax spores and a differing immunisation schedule might explain this difference. Decreased motivation could result when the threat of anthrax subsided. Non-availability of vaccine when reinforcement personnel returned to parent units was unlikely as reinforcements constituted an increasing proportion of those receiving subsequent immunisations. Adverse reactions were not the cause of this. Others (5,6) found an increasing proportion had adverse reactions as time passed. However, adverse reactions decreased in the present study with those affected being undeterred from accepting subsequent immunisation.
Previous immunisation

Those immunised against anthrax 7 years previously were more willing to undergo immunisation than naive subjects and were more likely to report adverse reactions after the first immunisation of a new series. Recent evidence (7) suggested recipients of biological or multiple immunisations were more likely to satisfy the Centers for Disease Control and Prevention definition of "Gulf War syndrome" (8). Nevertheless, the small group of British Gulf War veterans in the present study were not deterred from accepting anthrax re-immunisation and, presumably, had not associated previous immunisation with unduly adverse reactions or persisting symptoms. A previous report (5) mentioned two mill workers processing imported goat hair who were inadvertently immunised against anthrax when they had had clinical cutaneous anthrax 7 and 14 years previously. Both experienced severe local reactions at 24 and 48 hours after immunisation indicating that adverse reactions can occur in those re-exposed to anthrax antigens many years later.

Prevalence of adverse reactions

The overall prevalence of adverse reactions (40%) was similar to that (35%) reported previously (5) but then the great majority of reactions were local with just 2 subjects (a prevalence of 0.2%) experiencing systemic reactions (see below).

Nature and severity of adverse reactions and associated incapacity

The distribution of adverse reactions (local, systemic and local with systemic) remained constant. Previously a decreasing prevalence of local reaction and an increasing prevalence of local with systemic reaction were reported (6). Distribution of severity between categories (mild, moderate and severe) remained constant with only a minority (21%) reporting severe symptoms. Of the 95 experiencing any type of adverse reaction at any time (the prevalence of adverse reaction decreased with time), 43 (45%) reported associated incapacity and of these, 27 gave the duration of incapacity. This lasted not more than 48 hours in the majority (17=63%). Thus, 18% of those receiving the initial immunisation were incapacitated for 48 hours but only 7% of those receiving the final immunisation. In most (74%), pain at the site of injection prevented lifting or driving for 48 hours. Previously, it was claimed that no incapacity occurred after anthrax immunisation (6).

Relationship between adverse reaction and immune response

Darlow, Belton and Henderson (6) found no consistent relationship between the severity of reaction and the toxin-neutralising antibody titre assessed by bioassay. The present study using a more sophisticated method to estimate antibody concentration supports this.

What prevented acceptance of immunisation?

No positive evidence has emerged to account for the failure to accept immunisation. Partly this was due to the omission of systematic enquiry whether members of the field hospital staff feared the risk of "Gulf War Syndrome" arising following anthrax immunisation and of why those receiving the first immunisation did not deter re-immunisation and that antecedent adverse reactions during the present series were not prevent subsequent immunisation have been discussed above. Diminishing likelihood of deployment with the passage of time cannot be discounted as a cause of failure to complete the immunisation schedule.

Measures to improve the completion of the immunisation schedule

Anthrax immunisation is essential for protection. If compulsory immunisation for military personnel is unacceptable, a superior antigen inducing long lasting immunity following a single immunisation is required. Improvement in voluntary acceptance of this could result if potential recipients are shown the results of animal experiments which demonstrate dramatically the benefit of immunisation (3). Side effects are unlikely to deter subjects from receiving immunisation provided these do not exceed the magnitude of those reported here.

Acknowledgments

The authors are grateful to the members of 33 Field Hospital RAMC without whose co-operation this study would not have been possible and to Messrs TJ Townend and LWJ Baillie of Chemical & Biological Defence Sector, DERA Porton Down, Salisbury who kindly assayed antibody concentrations.
Footnote:
Data not shown were made available for the scrutiny of reviewers and are available on request.

References
Adverse Reactions to Anthrax Immunisation in a Military Field Hospital

SC Hayes and MJ World

*J R Army Med Corps* 2000 146: 191-195
doi: 10.1136/jramc-146-03-07

Updated information and services can be found at:
http://jramc.bmj.com/content/146/3/191

These include:

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/